003120.KS
Ilsung Is Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 20,650.00
+0.49%Year over year
Reported trailing growth
- Revenue
- -5.2%
- EBITDA
- —
- EBIT
- +23.3%
- EPS
- -66.4%
- Free cash flow
- +149.4%
- Operating cash flow
- +9950.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +1.6%
- EBITDA
- —
- EBIT
- +35.3%
- Net income
- -77.9%
- EPS
- -61.2%
- Free cash flow
- +192.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026